<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053141_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133937</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012ES112260</safetyreportid>
		<primarysourcecountry>ES</primarysourcecountry>
		<occurcountry>ES</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121205</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121205</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012ES112260</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>ES</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>ES</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>50</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>1</patientsex>
			<reaction>
				<primarysourcereaction>Inadequate antidiuretic hormone secretion</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Inappropriate antidiuretic hormone secretion</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Inappropriate antidiuretic hormone secretion</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201010</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101020</reactionenddate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood corticotrophin</testname>
				<testresult>803</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood corticotrophin</testname>
				<testresult>803</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111011</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood pressure</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood sodium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101020</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111007</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111011</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111007</testdate>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20111011</testdate>
				<testname>Blood urea</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Urine analysis</testname>
				<testresult>271.805</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Urine analysis</testname>
				<testresult>271.805</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRILEPTAL</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationnumb>21-014</drugauthorizationnumb>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>300 mg, daily</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2010</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20101001</drugenddate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OXCARBAZEPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>RAMIPRIL </medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20100920</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20101007</drugenddate>
				<drugtreatmentduration>18</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RAMIPRIL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inappropriate antidiuretic hormone secretion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DOBUPAL</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>150 mg, UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Depression</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>VENLAFAXINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>LYRICA</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>OMEPRAZOLE</medicinalproduct>
				<obtaindrugcountry>ES</obtaindrugcountry>
				<drugauthorizationcountry>ES</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>20 mg, daily</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>200911</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OMEPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012ES112260, is an initial spontaneous report received from a physician via ES-AGEMED (336101440) Health Authority on 05 Dec 2012. This report refers to 50-year-old male patient. Concomitant medication included omeprazole (manufacturer unknown). The patient received Trileptal (oxcarbazepine) for pain at a dose of 300 mg daily from 2010 (date unspecified). The patient also received ramipril (manufacturer unknown) for hypertension, Dobupal (venlafaxine hydrochloride) 150 mg for depression and Lyrica (pregabalin) for pain. On an unknown date in Oct 2010; the patient was hospitalized due to inadequate antidiuretic hormone secretion. The treatment with Trileptal and ramipril was stopped on 07 Oct 2010. On an unknown date, the lab data revealed, Na (blood sodium) 122 (normal range not provided), arterial tension was 130/89 (normal range not provided), cardiac frequency was 74 (normal range not provided), urine Na was 46 (normal range not provided), K (potassium) was 27 (normal range not provided), urea was 116.9 (normal range not provided), urine was 271.805 Mmol/L (normal range not provided) and ACTH (adrenocorticotropic hormone) was 803 Mmol/L. On 07 Oct 2011, urea was 4.1, Na (blood sodium) was 120, K was 4.1 and creatinine was 75 (normal range not provided). On 11 Oct 2011, creatinine was 74, urea was 4.8, Na was 132 and K was 4.39. Action taken with Dobupal and Lyrica was unknown. The event outcome was reported as recovered on 20 Oct 2010. The ES-AGEMED Health Authority considered the event as serious (hospitalization). The ES-AGEMED Health Authority assessed the event as suspected.</narrativeincludeclinical>
				<sendercomment>Medical assessment for Trileptal: It is difficult to make a causality assessment based on reported information.

Comment for Ramipril: Based on review of available information, the event syndrome of inappropriate antidiuretic hormone secretion is confounded by multiple medications.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
